Oncology (theme testing)

Our Oncology Work

We generate fit-for-purpose real-world datasets to advance your oncology research and treatment breakthroughs.

Breakthroughs in next-generation therapies bring hope for better outcomes to cancer patients. With the emergence of new advancements in treatment brings complex inquiries regarding development path and treatment sequencing for drug development programs.

At Pulse, we connect your complex research requirements with our unique real-world datasets and fit-for-purpose real-world data (RWD) solutions to handle complex questions throughout every stage of your drug development process.

The Pulse Infoframe Difference

For the past decade, Pulse has been leading the transformation in the generation of real-world evidence (RWE) for melanoma, uveal melanoma, and lung cancer indications. We take a collaborative and comprehensive approach to the curation of our exclusive dataset, to better address your research requirements for today and tomorrow.  What sets our transformative approach apart: 

Comprehensive ongoing real-world dataset:

Continuous contribution of data byo more than 50 global sites with data from over 6,500 cancer patients

Leading researchers

The melanoma, uveal melanoma, and lung cancer registries are designed and managed in collaboration with experts in their field

Fit-for-purpose use cases addressed

Including patients’ lived experience as a comparator arm, development of biomarkers and endpoints, therapy sequencing, pricing and reimbursement, recruitment for clinical trials, post-marketing & safety and more.

Continued associations with medical centers and patients

Established connections and foundation to enable the reconsenting of patients to support evolving research objectives. 

Flexible design to meet evolving objectives:

Configurable and extendable platform design enabling speed to study startup and the expansion of existing datasets and variables.

Experienced biostatisticians

Enabling the application of statistical methods to identify optimal lines of therapy, dosing, and more. 


Our Oncology Registries

Meeting your research objectives demands hard-to-obtain data and intricate clinical interpretation to generate supporting evidence. Our exclusive oncology solutions encompass clinical operation teams, indication-specific data, and the availability of oncology sites, key opinion leaders, investigators, and patients on an ongoing basis. This holistic approach enables Pulse to deliver customized datasets and analyses tailored to meet your specific requirements. Our melanoma, uveal melanoma, and lung data model combines retrospective and prospective methods including: 

  • Patient Status and Disease Diagnosis 
  • Disease Progression Insights 
  • Treatment Modality, outcomes, and safety 
  • Health-related quality of life 
  • Patient-reported outcomes measures 


Uveal Melanoma

Lung Cancer


Global Melanoma Research Network 

The Global Melanoma Research Network (GMRN) is a pioneering initiative launched in 2012 in collaboration with Oncologist Dr. Scott Ernst from the London Health Science Centre. Our primary goal was to give physicians a centralized location to share insights to help accelerate research and enhance the quality of care for individuals affected by melanoma.

Over the years, GMRN has grown and adapted to address a broader spectrum of skin cancers, now incorporating sub-registries for Merkel Cell Carcinoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma within the overarching melanoma research network.

By joining our network, you become an integral part of a collaborative community of over 5,000 melanoma participants who have generously contributed data for over a decade, providing support and valuable insights for individuals navigating the complexities of melanoma and related skin cancers.

Melanoma Dashboard
Contact Us to Get Started

Uveal Melanoma

About the Ocular Melanoma Natural History Study (OMNi) 

The Ocular Melanoma Natural History Study (OMNi), a groundbreaking initiative that commenced in 2020 through collaboration with a global team of primary investigators based in North America, Europe, and Australia. Our collective mission: to establish a dynamic and collaborative network providing unprecedented insights into patients with uveal melanoma on a worldwide scale. 

Since its inception, OMNi has rapidly evolved into one of the largest datasets of uveal melanoma patients globally. This comprehensive registry boasts an array of expanded variables, covering crucial aspects such as tumor characteristics, systemic therapies, biomarkers, biobanking, distant metastasis and treatment, ECOG status, surveillance, comorbidities, and much more.  

Contact Us to Get Started

Lung Cancer

About Pan-Canadian Lung Cancer Observational Study (PALEOS): 

The Pan-Canadian Lung Cancer Observational Study, an initiative launched in 2020 to shed light on the natural history and real-world treatment patterns of diverse subgroups of lung cancer patients across Canada. To date, the evidence generated from this registry has been published in two manuscripts and multiple abstractsThe primary investigator Dr. Parneet K. Cheema was also featured in Oncology Treatment Today, on how real-world evidence accelerates access to life-saving medications. * 

Contact Us to Get Started

Meet our Primary Investigators

Dr. Scott Ernst- LHSC, ON

Medical Oncologist. Professor, Department of Oncology, Schulich School of Medicine and Dentistry, Western University.

Testing heading 6 out as a better text size and look


Data from the Global Melanoma Research Network has been used in over 20 publications and posters since the registry launched and is regularly featured in posters presented by our team, researchers as well as registry sponsors. Insights have been shared in academic journals such as Current Oncology, Annals of Oncology, and at some of the biggest industry conferences in the world including ASCO, ESMO and ISPOR.

Mucosal melanoma, epidemiology, clinical presentation and outcome in Canada

Use of clinical information for prediction of disease progression in Melanoma patients

Metastatic BRAF-Mutated Cutaneous Melanoma

Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma

Prevalence and impact of BRAF mutation testing in patients with metastatic melanoma

Determining predictors for sentinel node biopsy in thick melanoma

The use of ipilimumab in the treatment of metastatic melanoma in the over 70 population in Canada

Survival Outcomes for Cutaneous Melanoma of the Head and Neck in Canada

Impact of IL2 for In-transit Melanoma in two Canadian Centers

Utilization of RWD to Assess the Efficacy of Immune Checkpoint Inhibitors (ICI) in Elderly Patients with Metastatic Melanoma

Epidemiology, management patterns and costs of melanoma

Resource utilization and costs of managing patients with advanced metastatic melanoma

Health care resource utilization modeling in patients treated with Ipilimumab

Read about how machine learning and artificial intelligence helped determine treatment choices for melanoma patients. Presented at ISPOR 2023

View Poster

This poster was presented at World Sleep 2022.

View Poster

CATNAP® in the Press

Looking for more information?
Have more questions?